Administration of chondroprotector piascledine in the treatment of secondary osteoarthritis in patients with gout
https://doi.org/10.14412/1995-4484-2007-66-71
Abstract
Objective. To study clinical efficacy and safety of piascledine in the treatment of osteoarthritis (OA) in pts with gout.
Material and methods. 30 pts older than 35 years with gout and concomitant OA were included. During 2 months they received piascledine 300 mg/day. All pts fulfilled Wallace S. criteria for gout and ACR criteria for OA. Exclusion criteria: renal and hepatic failure,
severe infections, childbearing potential female, administration of other chondroprotectors. Clinical and laboratory examination was performed before and after 2 months of treatment with piascledine.
Results. After 2 months of treatment pain on VAS decreased at rest (p<0,01) and at movement (p<0,05). There were no adverse events leading to withdrawal of the drug. Uric acid serum level, measures of lipid and carbohydrate metabolism, renal and hepatic function did not significantly differ from baseline.
Conclusion. Piascledine administration in gout pts with OA is safe, effectively decrease pain and do not influence serum level of uric acid.
About the Authors
M. S. Eliseev
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
V. G. Barskova
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
E. L. Nasonov
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
References
1. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практич. ревматол., 2004, 1, 5-7
2. Li-Yu J., Clauburne G., Sieck M. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol., 2001, 28, 577-580
3. Pascual E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of patients with untreared gout. Arthr. Rheum., 1991, 42 (2), 141-145
4. Pascual E., Battle-Gualda E., Martinez A. et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med., 1999, 131, 758-759
5. Di Giovine F.S., Malawista S.E., Thornton E., Duff G.W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. Clin Invest., 1991, 87(4), 1375–1381
6. Inokuchi T., Moriwaki Y., Tsutsui H. et al. Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 2006, 33(1), 21-27
7. Martinon F., Petrilli V., Mayor A. et al. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081), 237-241
8. Schweyer S., Hemmerlein B., Radzun H.J., Fayyazi A. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows. Arch. 2000, 437, 534-539
9. Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions. Clin. Cornestone, 1999, 2, 17-31
10. Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch. Intern. Med, 2005, 165, 742-748
11. Б арскова В.Г. Метаболический синдром и кардиоваскулярные нарушения при подагре. Дисс. д.м.н., М., 2006, 291
12. Gutman A.B. Gout, in Beeson PB, McDermott W (eds): Textbook of Medicine (ed 12). Philadelphia, Saunders, 1967, 1238
13. Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York, 1976, 512
14. Maheu E., Coste P. Piascledine 300: Clinical apdate. 1998, 1-26
15. Blotman F., Maheu E., Wulwic A., et al. Efficasy and safety of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Rev. Rhum. (Engl. Ed.), 1997, 64(12), 825-834
16. Maheu E., Mazieres B., Valat J.P. et. al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthr. Rheum., 1998, 41(1), 81-91
17. Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Nrials (ESCISIT). Ann. Rheum. Dis., 2003, 62, 1145-1155
18. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. Rheum., 1977, 20, 895-900
19. Altman R., Asch E., Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Ibid., 1986, 29(8), 1039-1045.
20. Altman R., Alarson G., Appelrouth D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Rheum., 1991, 34, 505-514
21. Huskisson E.S. Measurement of a painful syndrome. Lancet, 1974, 2, 1127-1131
22. Martel-Pelletier J., McCollum R., DiBattista J. et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: identification as the type I receptor and analysis of binding kinetics and biologic function. Arthr. Rheum., 1992, 35, 530-540
23. Henrotin Y.E., Labasse A.H., Jaspar J.M. et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglaldin E2 production by human articular chondrocytes. Arthr. Rheum., 1998, 17, 31-39
24. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthr. Res. Ther., 2007, 9, R28
25. Елисеев М.С., Барскова В.Г., Насонова В.А. Клиническое значение метаболического синдрома при подагре. Клинич. геронтология, 2006, 2, 29-33
26. Choi H.K., Atkinson K., Karlson E.W. et al. Purinerich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med., 2004, 350 , 1093- 1103
Review
For citations:
Eliseev M.S., Barskova V.G., Nasonov E.L. Administration of chondroprotector piascledine in the treatment of secondary osteoarthritis in patients with gout. Rheumatology Science and Practice. 2007;45(4):66-71. (In Russ.) https://doi.org/10.14412/1995-4484-2007-66-71
Views:
6835
Email this article 